Asgard Therapeutics is a private preclinical-stage biotech company pioneering in vivo direct reprogramming for cancer immunotherapy. Since the end of 2021, Asgard is supported by Novo Holdings, Boehringer Ingelheim Venture Fund, and Industrifonden which co-led a €6M Seed round to achieve POC of the lead program. Prior to that, Asgard's scientific founders had been working on the initial proof-of-principle in Lund University supported by €1,5M-worth of European and local non-dilutive grants.